A Phase 1 Study to Assess the Safety and Tolerability of Single and Multiple Ascending Doses of SAN711 in Healthy Participants
Latest Information Update: 06 Jul 2023
At a glance
- Drugs SAN-711 (Primary)
- Indications Neuropathic pain; Pruritus; Trigeminal neuralgia
- Focus Adverse reactions; First in man
- Sponsors Saniona
- 30 Jun 2022 According to a Saniona media release, this trial was conducted under the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA).
- 30 Jun 2022 Status changed from recruiting to completed, according to a Saniona media release.
- 30 Jun 2022 Results published in the Saniona Media Release.